Concepedia

Antibody Developability Assessment

Antibody Developability Assessment is a systematic evaluation framework that distinguishes itself by predicting the likelihood of successful therapeutic antibody development through the analysis of biophysical, biochemical, and pharmacokinetic properties early in the discovery process.

93

Publications

5.6K

Citations

713

Authors

182

Institutions

Publications per year

2017–2026

48

Variants

Antibody Developability Profiling

Parents

Publications

93

Biophysical properties of the clinical-stage antibody landscape

Tushar Jain, Tingwan Sun, Stéphanie Durand et al. · Proceedings of the National Academy of Sciences · 2017 · 634 citations · Full text

, , +17

An assessment of histone-modification antibody quality

Thea A. Egelhofer, Aki Minoda, Sarit Klugman et al. · Nature Structural & Molecular Biology · 2010 · 444 citations · Full text

, , +11

Five computational developability guidelines for therapeutic antibody profiling

Matthew I. J. Raybould, Claire Marks, Konrad Krawczyk et al. · Proceedings of the National Academy of Sciences · 2019 · 368 citations · Full text

, , +17

In silico selection of therapeutic antibodies for development: Viscosity, clearance, and chemical stability

Vikas Sharma, Thomas W. Patapoff, Bruce Kabakoff et al. · Proceedings of the National Academy of Sciences · 2014 · 259 citations · Full text

, , +17

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening

Marc Bailly, Carl Mieczkowski, Veronica Juan et al. · mAbs · 2020 · 223 citations · Full text

, , +9

1–5 of 93

Authors

713

  1. LF
    Laurence Fayadat‐Dilman

    Merck & Co., Inc., Rahway, NJ, USA (United States), United States

    3 publications · 291 citations

    3

    h-index

  2. NL
    Nikolai Lorenzen

    Novo Nordisk (Denmark), Denmark

    3 publications · 212 citations

    3

    h-index

  3. YX
    Yingda Xu

    Adimab (United States), United States

    3 publications · 843 citations

    3

    h-index

  4. PS
    Pietro Sormanni

    University of Cambridge, United Kingdom

    3 publications · 212 citations

    3

    h-index

  5. TJ
    Tushar Jain

    Adimab (United States), United States

    3 publications · 843 citations

    3

    h-index

1–5 of 713

Institutions

182

  1. University of Cambridge

    Cambridge, United Kingdom

    6 h-index

    20 publications

    3.2K citations

  2. Pfizer (United States)

    New York, United States

    6 h-index

    29 publications

    1.2K citations

  3. Novo Nordisk (Denmark)

    Copenhagen, Denmark

    4 h-index

    20 publications

    1.6K citations

  4. University of Oxford

    Oxford, United Kingdom

    4 h-index

    17 publications

    2.4K citations

  5. Amgen (United States)

    Thousand Oaks, United States

    4 h-index

    60 publications

    2K citations

  6. Centre National de la Recherche Scientifique

    Paris, France

    4 h-index

    10 publications

    368 citations

  7. United States Food and Drug Administration

    Silver Spring, United States

    3 h-index

    6 publications

    374 citations

  8. AbbVie (United States)

    North Chicago, United States

    3 h-index

    8 publications

    167 citations

1–8 of 182

Venues

  1. mAbs

    21 publications · 1.4K citations

    19

    h-index

  2. Journal of Pharmaceutical Sciences

    8 publications · 395 citations

    8

    h-index

  3. Journal of Immunological Methods

    4 publications · 133 citations

    4

    h-index

  4. Methods in molecular biology

    Book series · 3 publications · 88 citations

    3

    h-index

  5. Proceedings of the National Academy of Sciences

    PNAS · 3 publications · 1.3K citations

    3

    h-index

1–5